anti-TNFainterleukin (IL) 23inflammatory bowel diseaseIBDJoanna Briggs InstituteACTadvanced combination therapy
…inhibitors. Pooled analyses demonstrated low rates of SAEs (eg, anti-TNFa plus integrin inhibitors: 2.7%, 95% CI 0.22% to 6.86%) and disc…